Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin
hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as
bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells
to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
substances to them. It is not yet known whether giving combination chemotherapy together with
or without bevacizumab is more effective in treating patients with nonmetastatic breast
cancer.
PURPOSE: This randomized phase III trial is studying how well giving combination chemotherapy
works compared with giving combination chemotherapy together with bevacizumab in treating
patients with nonmetastatic breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust